(AUPH) Aurinia Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.965m USD | Total Return: 84% in 12m
Avg Turnover: 17.8M
Qual. Beats: 0
Rev. Trend: 99.1%
Qual. Beats: 0
Warnings
Earnings expected to drop: P/E 7.1 → Forward 22.0
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Below Avwap Earnings
Tailwinds
Confidence
Aurinia Pharmaceuticals Inc. (AUPH) is a Canadian biopharmaceutical firm specializing in therapies for autoimmune diseases. The company’s primary commercial product is LUPKYNIS (voclosporin), an oral treatment approved for adults with active lupus nephritis in the United States and Japan.
Operating within the biotechnology sector, the company utilizes a research-intensive business model focused on addressing high unmet medical needs through targeted drug development. In addition to its commercialized therapy, Aurinia is developing aritinercept, a dual inhibitor aimed at treating various autoimmune conditions by targeting specific B cell-activating factors.
Biotechnology firms often face significant capital requirements and regulatory hurdles during the transition from clinical development to commercial scaling. Investors may find it useful to review the detailed valuation metrics available on ValueRay to better understand the companys financial positioning. Headquartered in Edmonton, Canada, Aurinia has maintained its focus on the immunology space since its founding in 1993.
- LUPKYNIS prescription growth and market penetration drive quarterly revenue performance
- Strategic restructuring and cost reduction measures improve path to profitability
- Patent litigation outcomes impact long-term exclusivity for voclosporin in US markets
- Pipeline diversification through aritinercept development reduces single-product dependency risk
- Potential acquisition interest from larger biopharma firms influences stock volatility
| Net Income: 298.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.23 > 0.02 and ΔFCF/TA 10.19 > 1.0 |
| NWC/Revenue: 132.0% < 20% (prev 136.4%; Δ -4.44% < -1%) |
| CFO/TA 0.23 > 3% & CFO 165.8m > Net Income 298.2m |
| Net Debt (-310.1m) to EBITDA (161.8m): -1.92 < 3 |
| Current Ratio: 5.55 > 1.5 & < 3 |
| Outstanding Shares: last quarter (137.6m) vs 12m ago -0.92% < -2% |
| Gross Margin: 89.74% > 18% (prev 0.88%; Δ 8.89k% > 0.5%) |
| Asset Turnover: 48.55% > 50% (prev 48.98%; Δ -0.44% > 0%) |
| Interest Coverage Ratio: 14.61 > 6 (EBITDA TTM 161.8m / Interest Expense TTM 9.74m) |
| A: 0.54 (Total Current Assets 480.2m - Total Current Liabilities 86.6m) / Total Assets 724.0m |
| B: -0.85 (Retained Earnings -615.0m / Total Assets 724.0m) |
| C: 0.23 (EBIT TTM 142.4m / Avg Total Assets 614.4m) |
| D: 3.01 (Book Value of Equity 470.8m / Total Liabilities 156.4m) |
| Altman-Z'' = 5.52 = AAA |
| DSRI: 1.01 (Receivables 49.2m/40.4m, Revenue 298.3m/247.3m) |
| GMI: 0.98 (GM 89.74% / 88.24%) |
| AQI: 23.88 (AQ_t 0.24 / AQ_t-1 0.01) |
| SGI: 1.21 (Revenue 298.3m / 247.3m) |
| TATA: 0.18 (NI 298.2m - CFO 165.8m) / TA 724.0m) |
| Beneish M = 10.87 (Cap -4..+1) = D |
As of May 24, 2026, the stock is trading at USD 15.22 with a total of 967,683 shares traded.
Over the past week, the price has changed by -0.39%,
over one month by -7.31%,
over three months by +2.63% and
over the past year by +84.04%.
Aurinia Pharmaceuticals has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy AUPH.
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17 | 11.7% |
P/E Forward = 21.978
P/S = 6.5876
P/B = 3.4505
Revenue TTM = 298.3m USD
EBIT TTM = 142.4m USD
EBITDA TTM = 161.8m USD
Long Term Debt = 50.5m USD (estimated: total debt 68.6m - short term 18.1m)
Short Term Debt = 18.1m USD (from shortTermDebt, last quarter)
Debt = 68.6m USD (from shortLongTermDebtTotal, last quarter) (leases 68.6m already included)
Net Debt = -310.1m USD (calculated: Debt 68.6m - CCE 378.8m)
Enterprise Value = 1.65b USD (1.97b + Debt 68.6m - CCE 378.8m)
Interest Coverage Ratio = 14.61 (Ebit TTM 142.4m / Interest Expense TTM 9.74m)
EV/FCF = 10.00x (Enterprise Value 1.65b / FCF TTM 165.5m)
FCF Yield = 10.00% (FCF TTM 165.5m / Enterprise Value 1.65b)
FCF Margin = 55.50% (FCF TTM 165.5m / Revenue TTM 298.3m)
Net Margin = 99.97% (Net Income TTM 298.2m / Revenue TTM 298.3m)
Gross Margin = 89.74% ((Revenue TTM 298.3m - Cost of Revenue TTM 30.6m) / Revenue TTM)
Gross Margin QoQ = 91.63% (prev 89.01%)
Tobins Q-Ratio = 2.29 (Enterprise Value 1.65b / Total Assets 724.0m)
Interest Expense / Debt = 14.19% (Interest Expense 9.74m / Debt 68.6m)
Taxrate = 21.79% (9.57m / 43.9m)
NOPAT = 111.4m (EBIT 142.4m * (1 - 21.79%))
Current Ratio = 5.55 (Total Current Assets 480.2m / Total Current Liabilities 86.6m)
Debt / Equity = 0.12 (Debt 68.6m / totalStockholderEquity, last quarter 567.6m)
Debt / EBITDA = -1.92 (Net Debt -310.1m / EBITDA 161.8m)
Debt / FCF = -1.87 (Net Debt -310.1m / FCF TTM 165.5m)
Total Stockholder Equity = 462.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 48.54% (Net Income 298.2m / Total Assets 724.0m)
RoE = 27.68% (Net Income TTM 298.2m / Total Stockholder Equity 1.08b)
RoCE = 12.62% (EBIT 142.4m / Capital Employed (Equity 1.08b + L.T.Debt 50.5m))
RoIC = 18.61% (NOPAT 111.4m / Invested Capital 598.5m)
WACC = 8.47% (E(1.97b)/V(2.03b) * Re(8.38%) + D(68.6m)/V(2.03b) * Rd(14.19%) * (1-Tc(0.22)))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -42.22 | Cagr: -1.94%
[DCF] Terminal Value 77.58% ; FCFF base≈124.9m ; Y1≈143.2m ; Y5≈210.8m
[DCF] Fair Price = 26.56 (EV 3.11b - Net Debt -310.1m = Equity 3.42b / Shares 128.6m; r=8.47% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.19 | # QB: 0
Revenue Correlation: 99.11 | Revenue CAGR: 26.98% | SUE: 0.22 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.25 | Chg30d=+12.50% | Revisions=+20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.24 | Chg30d=+15.48% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=0.96 | Chg30d=+14.97% | Revisions=+20% | GrowthEPS=-53.6% | GrowthRev=+14.6%
EPS next Year (2027-12-31): EPS=1.12 | Chg30d=+33.89% | Revisions=+20% | GrowthEPS=+16.5% | GrowthRev=+19.3%
[Analyst] Revisions Ratio: +20%